Psilocybin-Assisted Therapy for Depression
Psilocybin administered once, in tightly controlled clinical settings with trained therapists present, is one of the most actively researched directions in psychiatry for treatment-resistant depression — with real, published phase 2 trials, but also real methodological limitations and a legal status that, in Poland and most of Europe, does not allow its legal use outside a strictly supervised clinical trial.
Number of studies
3
Safety
Requires caution
Time to effects
Subjective, acute psychedelic effects appear 20–40 minutes after dosing and last 4–6 hours. The antidepressant effect, if it occurs, tends to be noticeable within days of the session, and in the COMPASS Pathways trial was still partially measured at 12 weeks — though in some patients it faded over time and required consideration of another session or a return to standard treatment.
Who it's for
Table of contents
TL;DR
Psilocybin administered once, in tightly controlled clinical settings with trained therapists present, is one of the most actively researched directions in psychiatry for treatment-resistant depression — with real, published phase 2 trials, but also real methodological limitations and a legal status that, in Poland and most of Europe, does not allow its legal use outside a strictly supervised clinical trial.
- →In phase 2 trials — significant reduction of treatment-resistant depression symptoms after one or two sessions, in some patients faster than with classic SSRIs
- →In some trials, the antidepressant effect persisted for weeks to months after a single session, distinguishing this model from drugs requiring daily intake
- →The structured therapeutic protocol (preparation, session, integration) gives patients space to work psychologically on the underlying causes of depression, not just symptom relief
| Substance | Psilocybin — a tryptamine, prodrug of psilocin, partial agonist at the 5-HT2A receptor |
|---|---|
| Source | Psilocybe mushrooms; in clinical trials — a synthetic, standardized form |
| Studied context | Psilocybin-assisted therapy — one or two supervised sessions, with preparation and integration |
| Evidence level | Early — phase 2 trials, small samples, significant methodological limitations (functional unblinding) |
| Legal status in Poland | Schedule I-P psychotropic substance — illegal outside an approved clinical trial |
| Regulatory status | Not registered as a drug in Poland, the EU or the US (as of 2026) — clinical trials only |
| Interactions | Yes — risky interaction with SSRIs/MAOIs, psychiatric contraindications |
Understand
Overview
Psilocybin is a naturally occurring psychoactive compound found in Psilocybe mushrooms, converted in the body to psilocin — the active metabolite responsible for its action on serotonin receptors in the brain. Over the past decade this compound has become the subject of one of the most intensively funded research directions in psychiatry: psilocybin-assisted therapy for treatment-resistant depression, meaning depression that has not responded adequately to at least two prior, standard lines of pharmacological treatment.
It's worth clearing up a potential misunderstanding right away: the psilocybin therapy studied in clinical trials has nothing to do with unsupervised, self-administered use of psilocybin mushrooms at home. In research protocols, a single, carefully measured dose is given once or twice in a clinical office, under the constant supervision of two trained therapists, after several preparatory sessions, with integration support guaranteed afterward. The several-hour drug session itself — the "trip" — is only one, relatively short element of a much longer, structured therapeutic process.
Interest in this approach stems from two factors. The first is the desperate need for new treatment options in treatment-resistant depression — a group of patients in whom conventional antidepressants (SSRIs, SNRIs and others) have failed, and where the risk of chronic suffering and suicide is particularly high. The second is the genuinely promising, though still limited, results of phase 2 clinical trials — including two key studies discussed further below: the COMPASS Pathways trial published in the New England Journal of Medicine in 2022, and an earlier trial from the Johns Hopkins University team.
It's equally important to stress the real limitations of this evidence base before getting carried away by media enthusiasm. The biggest, systemic methodological problem in most psychedelic trials is so-called functional unblinding — a participant who received 25 mg of psilocybin typically knows within minutes that they didn't get placebo or a low control dose, because the substance's strongly perception-altering subjective effects are hard to mistake for anything else. This means that even in formally "double-blind" trials, participants themselves (and sometimes the therapists assessing them) know which group they're in, which can systematically inflate reported effects through expectation and an unusually strong placebo effect.
A second important limitation is small sample sizes — even the most important, most frequently cited trials have enrolled anywhere from several dozen to a couple hundred participants, a small number compared to the registration standards for new psychiatric drugs, which typically require thousands of participants in phase 3 trials. As of 2026, psilocybin-assisted therapy is still at the phase 2 and early phase 3 stage — it is not a registered drug approved for general use, and its ultimate regulatory status remains uncertain.
A third, absolutely critical element is the legal status of the substance itself. In Poland, as in most EU countries, psilocybin is a Schedule I-P psychotropic substance under the Act on Counteracting Drug Addiction — its possession, the cultivation of mushrooms containing it, and its use outside an approved clinical trial is illegal and carries criminal liability. Nothing in this entry should be read as encouragement for unsupervised, uncontrolled use of this substance — the therapeutic effects described here were observed exclusively under strict medical supervision, psychological preparation and post-session care that cannot be replicated at home.
History of use
Psilocybin mushrooms have a long history of ritual use in Mesoamerica, documented among peoples such as the Aztecs, who called them teonanácatl ("flesh of the gods"). Western science encountered them on a large scale after 1957, when R. Gordon Wasson published an account in Life magazine of his participation in a Mexican ritual involving mushrooms, which inspired Albert Hofmann (the discoverer of LSD) to isolate and synthesize psilocybin a year later. Early clinical research into its therapeutic potential was conducted in the 1960s, but a wave of uncontrolled, countercultural psychedelic use led to legal bans in most countries at the turn of the 1960s and 70s, effectively freezing legitimate scientific research into this class of substances for decades. A renaissance of clinical research began only at the start of the 21st century, mainly driven by centers such as Johns Hopkins University and Imperial College London, with a breakthrough moment being the FDA's granting of "breakthrough therapy" status to psilocybin therapy for treatment-resistant depression in 2018 and 2019, which significantly accelerated funding and the pace of subsequent phase 2 trials.
Mechanism of action
Psilocybin itself is a prodrug — after ingestion it is rapidly dephosphorylated in the body to psilocin, the active metabolite, which crosses the blood-brain barrier and acts as a partial agonist at the 5-HT2A serotonin receptor, densely distributed in the cerebral cortex, especially in its deeper layers. Activation of this receptor is considered the main, though not the only, mechanism behind the characteristic changes in perception, mood and thinking reported during sessions — confirmed by the fact that ketanserin, a selective 5-HT2A antagonist, blocks most of psilocybin's subjective effects in experimental studies.
At the level of neural networks, the leading mechanistic hypothesis, developed mainly by Robin Carhart-Harris's team, concerns psilocybin's effect on the so-called default mode network (DMN) — a set of interconnected brain regions active at rest, linked to introspection, rumination, and a rigid, fixed sense of self. Neuroimaging studies (fMRI) suggest psilocybin temporarily reduces the coherence and dominance of this network while increasing the overall "entropy" of brain activity — its variability and lower predictability relative to baseline. This observation underlies the so-called entropic brain hypothesis, according to which depression, especially its treatment-resistant forms, is associated with excessively rigid, repetitive patterns of brain activity and thinking, and psilocybin temporarily "loosens" that rigidity, opening a window of neuroplasticity in which psychological therapy can more effectively introduce new, healthier thought patterns.
It's worth clearly noting this hypothesis's status — it is a still-maturing, actively researched mechanistic model, not a settled, fully confirmed neurobiological fact. The DMN activity changes observed in imaging studies are real and reproducible, but their direct causal link to the clinical antidepressant effect is still not unambiguously proven — the observed neuroimaging changes could equally be a correlate rather than a direct cause of mood improvement, which may depend just as strongly on the subjectively experienced psychedelic experience itself (the so-called mystical-type experience) and its integration within the therapeutic work.
Animal studies and preliminary human data additionally point to a possible effect of psilocybin on structural neuroplasticity — increased dendritic spine density in the prefrontal cortex in rodents after a single psilocybin dose, which could theoretically explain the relatively fast and comparatively durable antidepressant effect after just one or two sessions, unlike the weeks needed for SSRIs to take effect. This mechanism, however, remains at the preclinical stage and has not yet been unambiguously confirmed as a direct cause of the clinical effect observed in humans.
Metabolism to psilocin
Psilocybin is a prodrug — after ingestion it is rapidly dephosphorylated to active psilocin, which crosses the blood-brain barrier.
5-HT2A receptor agonism
Psilocin acts as a partial agonist at the 5-HT2A serotonin receptor in the cortex — blocking this receptor with ketanserin eliminates most subjective effects.
Default mode network modulation
Neuroimaging (fMRI) shows a temporary reduction in DMN coherence and increased brain entropy — the basis of the entropic brain hypothesis.
Neuroplasticity window
Preclinical studies suggest increased dendritic spine density in the prefrontal cortex after one dose — a hypothesized mechanism for a relatively durable effect after a brief intervention.
Therapeutic integration
The clinical effect in research protocols depends heavily on structured therapeutic work before and after the session — the substance alone, without this context, has not been studied as a standalone intervention.
Evidence: early-stage — based on 3 studies in this database.
Benefits
Common myths
MythPsilocybin-assisted therapy is already legally available and registered as a drug for depression.
FactNo — as of 2026, psilocybin is not a registered drug in Poland, the European Union or the US. It's available exclusively within approved clinical trials; outside them, its possession and use is illegal under the Act on Counteracting Drug Addiction.
MythSince the trials are double-blind, the result can't be distorted by placebo effects or expectations.
FactBlinding is exceptionally hard to maintain in psychedelic trials — a participant who feels strong psychedelic effects usually quickly recognizes they didn't get the low control dose (so-called functional unblinding), which can inflate reported subjective effects regardless of the actual pharmacological action.
MythIf the therapy works in clinical trials, self-administered home microdosing or full doses will produce a similar therapeutic effect.
FactThe clinical effect in trials is inseparable from the entire therapeutic context — preparation, the presence of trained therapists during the session, and structured integration afterward. The absence of this context, the unpredictable content of mushrooms, and the lack of medical supervision mean entirely different, far less predictable, and potentially risky conditions.
Forms & variants
Psilocybin-Assisted Therapy for Depression comes in several forms that differ in bioavailability and use case — the form you pick genuinely matters for how effective the supplementation is.
Single-dose protocol (COMPASS Pathways)
A single 25 mg, 10 mg or 1 mg (control) dose given once, with a shorter preparation period than the Johns Hopkins protocol.
Best for: The model studied in the largest randomized phase 2b trial to date (Goodwin et al., 2022)
Two-dose protocol (Johns Hopkins / Imperial College)
Two sessions a few weeks apart, with more extensive psychological preparation before the first session.
Best for: The model studied in earlier, smaller pilot trials and in the comparative trial against escitalopram
Natural psilocybin mushrooms
Non-standardized psilocybin content, strongly variable between species and batches — never used in rigorous clinical trials due to the lack of dose reproducibility.
Best for: Not a clinically studied or recommended form in any context — included only for contrast with the synthetic, standardized form used in trials
Check your profile
Not sure which supplements actually make sense for you?
Answer a few short questions about your lifestyle, diet, sleep, and goals. VitMode will build your profile and show supplements worth considering — with reasoning and evidence strength.
Recommendations take your answers and the strength of the scientific evidence into account. A supplement's popularity has no bearing on whether it gets recommended.
Practice
Frequently asked questions
No. Psilocybin is a Schedule I-P psychotropic substance in Poland under the Act on Counteracting Drug Addiction. Its possession, the cultivation of mushrooms containing it, and its use outside an approved clinical trial is illegal. Access to it under controlled conditions is possible only as a participant in a registered clinical trial, if one is currently running and the person meets the eligibility criteria.
The evidence is real but still early. Two key phase 2 trials — COMPASS Pathways (Goodwin et al., NEJM 2022, n=233) and the Imperial College comparative trial against escitalopram (Carhart-Harris et al., NEJM 2021) — showed promising results, but both have significant limitations: relatively small samples, short follow-up periods, and nearly unavoidable functional unblinding of participants, which can inflate reported effects. Larger, longer phase 3 trials are needed before one can speak of an established, registration-ready evidence base.
Dramatically. Clinically studied therapy is a structured process involving several preparatory sessions, a single session with a precisely measured, synthetic dose under the constant supervision of two trained therapists, and integration sessions afterward. Self-administered consumption of natural mushrooms has none of these safety and psychological-support elements, and the active-substance content in mushrooms is strongly variable and unpredictable.
No. People with psychosis-spectrum disorders, bipolar disorder (especially with a history of manic episodes), and unstable cardiovascular disease are excluded from clinical trials due to documented risk of serious complications. Even within the qualified group of trial participants, cases of worsening suicidal ideation and episodes of intense distress during sessions have been recorded.
There isn't yet sufficient evidence to answer that affirmatively for the general population of depression patients. Research to date has focused on treatment-resistant depression — cases where standard treatment has already failed — not on replacing first-line treatment. What's more, chronic SSRI use may modify 5-HT2A receptors and thus affect the response to psilocybin, which is why SSRIs must be tapered off under medical supervision before trial participation.
It means a trial participant quickly recognizes whether they received the active substance or placebo/a low control dose, because the strong, subjective psychedelic effects are hard to mistake for anything else. This weakens the credibility of a trial's "blinding" — both the participant and sometimes the therapist assessing them may unconsciously inflate the perceived therapeutic effect, knowing an active dose was given.
The most commonly reported are transient anxiety, disorientation, nausea, headaches, and increased blood pressure and heart rate during the session. In some participants, especially in high-dose groups, worsening suicidal ideation has also been recorded — which is why the presence of trained therapists ready to intervene throughout the entire session is an integral, non-negotiable safety element of this approach.
Dosage & timing
Typical dose
Exclusively within approved clinical trials: a single 25 mg dose (the "therapeutic" dose in the COMPASS Pathways trial) or a two-session protocol of 20–30 mg in the Johns Hopkins trial, each time under the direct supervision of two trained therapists in a clinical office.
Form
Synthetic, standardized psilocybin in capsule form — not natural mushrooms with variable, unpredictable active-substance content.
This is not a dosage for self-administration. Outside an approved clinical trial, psilocybin is an illegal psychotropic substance in Poland, and its uncontrolled use, especially without trained supervision and without a known, standardized active-substance content, carries significant psychological and legal risk.
Best times to take it
- In research protocols, the session usually lasts 6–8 hours, planned for a full day with no other commitments
- Preceded by several preparatory sessions with a therapist — building trust and setting intentions
- Followed by at least one, usually several, integration sessions in the days and weeks after taking the substance
- Most research protocols require tapering off SSRIs/SNRIs several weeks before the session under the supervision of the trial's treating physician
Safety
Side effects & contraindications
Possible side effects
Intense, temporary anxiety, fear or disorientation during the session itself (a "bad trip") — requires a trained therapist present and ready to intervene
Transient increase in blood pressure and heart rate during the session
Nausea, headaches in the hours after dosing
Worsening of suicidal ideation in some trial participants in the high-dose group — documented, among others, in the COMPASS Pathways trial as an adverse event requiring monitoring
Risk of triggering or worsening a psychotic episode in predisposed individuals
Rare, long-lasting cases of HPPD (hallucinogen persisting perception disorder) — persistent perceptual disturbances following psychedelic use, though data on frequency under controlled clinical conditions are limited
Psychological risk associated with incomplete integration of a difficult experience without adequate post-session therapeutic support
Contraindications
Psychosis-spectrum disorders (schizophrenia, schizoaffective disorder) and their family history — significantly elevated risk of triggering or worsening psychosis
Bipolar disorder, especially with a history of manic episodes — risk of triggering mania
Unstable cardiovascular disease — due to psilocybin's transient pressor and heart-rate effects during the session
Pregnancy and breastfeeding
Current, unstabilized suicide risk without adequate clinical safeguards
Interactions
SSRIs and SNRIs — chronic use may blunt (via 5-HT2A receptor downregulation) or otherwise modify the subjective response to psilocybin in not fully predictable ways
MAO inhibitors (MAOIs) — theoretical risk of dangerous serotonergic interaction; most research protocols require their discontinuation under medical supervision beforehand
Lithium — case literature describes a risk of seizures with concurrent use alongside psychedelic substances
Other psychoactive substances (alcohol, stimulants) taken around the session period — unpredictable effect on session course and safety
Is it worth taking?
Who it's for
- Exclusively participants in approved clinical trials on treatment-resistant depression, qualified after detailed psychiatric assessment
- People with depression that has not responded to at least two prior lines of standard pharmacological treatment — a typical trial inclusion criterion
- Not an option for the general population seeking mood enhancement, productivity or biohacking purposes — outside a clinical trial, this is illegal and unstudied for such use
Not for
- Psychosis-spectrum disorders (schizophrenia, schizoaffective disorder) and their family history — significantly elevated risk of triggering or worsening psychosis
- Bipolar disorder, especially with a history of manic episodes — risk of triggering mania
- Unstable cardiovascular disease — due to psilocybin's transient pressor and heart-rate effects during the session
- Pregnancy and breastfeeding
- Current, unstabilized suicide risk without adequate clinical safeguards
Evidence
Worth knowing
Psilocybin is a prodrug — its action is produced by its active metabolite, psilocin, through agonism at the 5-HT2A serotonin receptor.
In the COMPASS Pathways trial (2022), remission at week 3 after a 25 mg dose was achieved by 29.1% of participants — but the trial also recorded cases of worsening suicidal ideation in the high-dose group.
The FDA granted psilocybin therapy for treatment-resistant depression "breakthrough therapy" status as early as 2018-2019, which is not equivalent to drug approval.
In Poland, psilocybin is a Schedule I-P psychotropic substance — its possession and use outside a clinical trial carries criminal liability.
Studies
In the group receiving 25 mg of psilocybin, depression remission at week 3 occurred in 29.1% of participants, versus a significantly lower rate in the control group receiving 1 mg — alongside a risk of serious adverse events, including suicidal ideation, observed more frequently in the high-dose group.
Goodwin GM et al. (COMPASS Pathways), New England Journal of Medicine, 2022
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
Moderate evidenceGoodwin GM, Aaronson ST, Alvarez O, et al. · New England Journal of Medicine · 2022
A randomized, double-blind phase 2b trial (COMPASS Pathways) in 233 patients with treatment-resistant depression, comparing a single 25 mg, 10 mg, or 1 mg (control) dose of synthetic psilocybin with psychological support. In the 25 mg group, 29.1% of participants achieved remission at week 3, versus a significantly lower rate in the 1 mg group. The trial also recorded adverse events, including worsening suicidal ideation in some high-dose participants, and highlighted limitations from functional unblinding.
View studyTrial of Psilocybin versus Escitalopram for Depression
Moderate evidenceCarhart-Harris R, Giribaldi B, Watts R, et al. · New England Journal of Medicine · 2021
A phase 2 randomized trial in 59 patients with long-standing, moderate-to-severe depression, comparing two 25 mg doses of psilocybin with six weeks of escitalopram treatment. On the primary outcome (QIDS-SR-16), the between-group difference was not statistically significant (p=0.17), though secondary measures (remission: 57% for psilocybin vs 28% for escitalopram) favored psilocybin — without correction for multiple comparisons, which limits the strength of this conclusion.
View studyEffects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Early-stage evidenceDavis AK, Barrett FS, May DG, et al. · JAMA Psychiatry · 2021
A Johns Hopkins University pilot trial in 24 participants, randomized to immediate treatment with two psilocybin sessions (20 mg and 30 mg) or an 8-week waitlist. 71% of participants showed a clinically significant response at weeks 1 and 4. The authors themselves described the trial as proof-of-concept due to the small sample, lack of placebo control, and short, one-month follow-up.
View studySources & bibliography
- Goodwin et al. 2022 — New England Journal of Medicine
- Carhart-Harris et al. 2021 — New England Journal of Medicine
- Davis et al. 2021 — JAMA Psychiatry
The PubMed identifiers in this knowledge base were checked against NCBI records (October 2026). If you spot an error in a source, please let us know via the contact form.
Compare with similar entries
About the authors of this entry
Author
dr Katarzyna LewandowskaCardiologist
Katarzyna works as a cardiologist at a Warsaw teaching hospital and has spent years focused on cardiovascular prevention — trying, as she puts it, to convince people to change their habits before they end up on her ward, not after. She joined VitMode after a series of conversations with Anna at a lifestyle-medicine conference, where the two discovered they shared the same frustration: an internet full of contradictory claims about cholesterol, aspirin and heart supplements, with no clear signal of what's actually backed by research. She reviews content on cardiovascular health, lipid panels and pharmacological prevention, consistently distinguishing what helps a statistical population from what makes sense for a specific person. Off duty, she road-cycles — not for performance, but because, in her words, it's hard to write credibly about prevention without practicing it yourself.
61 publications on this site
Medical review
dr Piotr ZielińskiEndocrinologist
Piotr has practiced endocrinology for more than fifteen years, mostly in male hormonal disorders and metabolic health. He joined VitMode as a scientific consultant because, as he jokes, he got tired of explaining the same testosterone questions at every appointment and decided to write the answers down properly, once. He reviews content on hormone therapy, supplement pharmacology and drug interactions, making sure articles never turn into encouragement to self-supplement in situations that genuinely need diagnostics and medical supervision. His professional motto — "evidence first, enthusiasm second" — has come up more than once with a patient who arrived with a supplement plan they found online.
297 publications on this site
Related entries
4.5Ketamine for Depression Treatment
The only psychedelic or psychedelic-adjacent compound with a genuine, FDA- and EMA-approved registration for treatment-resistant depression — intranasal esketamine (Spravato) — alongside the still-unregistered but widely used off-label intravenous ketamine infusion offered at specialized clinics. A fast, unusual mechanism of action comes paired with real risks: dissociation during administration, abuse potential, and documented, serious bladder toxicity with chronic, non-medical misuse.
4.5Cortisol
The main stress hormone — essential for short-term survival, but problematic when chronically elevated.
4.7Sleep and Mental Health
Insomnia isn't just a symptom accompanying depression or anxiety — the largest randomized intervention trial in psychiatric history showed that improving sleep directly reduces paranoia, hallucinations, anxiety, and low mood.
4.4Heart Rate Variability (HRV)
The variability in the time between successive heartbeats is one of the best non-invasive indicators of autonomic nervous system balance — today available in nearly every sports watch.
4.2What is biohacking
From the DIY-biology movement through the Quantified Self to today's social-media-popular trend — what biohacking actually is in practice, and where science ends and marketing begins.
4.2Red Light Therapy (Photobiomodulation)
Exposure to red and near-infrared light has become a popular biohacking tool — with real, though still limited, evidence mainly in the context of skin health.
4.2At-Home Dermarolling and Microneedling
Micro-puncturing the skin with a roller covered in hundreds of microneedles — controlled, tiny injuries that trigger a healing response and collagen production. The procedure has solid support in the dermatology literature, above all for acne scarring, but performed at home it carries real, context-specific risks that simply don't exist in a dermatologist's office.
Related articles
PoradnikiMDMA-Assisted Therapy for PTSD: Does It Work? What the Trials Showed, and Why the FDA Rejected It
Two phase 3 trials (MAPP1 and MAPP2) showed strong, reproducible effects of MDMA-assisted therapy in post-traumatic stress disorder. In August 2024, the FDA nonetheless refused to approve the drug, citing serious concerns about data quality and reliability. It's a rare case where promising clinical results and a real, documented regulatory rejection coexist — and both sides of this story need to be understood to grasp the therapy's current status.
October 17, 2026
PoradnikiLSD Microdosing in Biohacking: What Do Placebo-Controlled Trials Actually Show?
LSD microdosing — taking sub-perceptual doses every few days to improve mood, creativity and focus — is one of the most popular practices in the biohacking community. The problem is that when rigorous, blinded trials with genuine placebo actually tested it, the reported benefits mostly didn't outperform placebo. It's a non-obvious, well-documented finding worth knowing before trying this practice — alongside its genuinely illegal status in Poland.
October 17, 2026
PoradnikiTestosterone, Depression, and Mood — Does Low Testosterone Affect Mental Health?
The link between low testosterone and low mood is real, but far more modest and less clear-cut than TRT clinic ads suggest — and testosterone therapy should never replace proven treatment for depression.
August 15, 2026
PoradnikiOmega-3 Fatty Acids and Depression: Why Do Form and Dose Determine Effectiveness?
"Omega-3 for depression" is one of those recommendations heard so often that almost no one asks about the details — and in this case, the details decide everything. Two independent meta-analyses consistently show that the antidepressant effect isn't a property of "omega-3 fatty acids" as a whole, but of a specific fatty acid, EPA, within a specific, moderate dose range — and exceeding that range paradoxically weakens the effect instead of strengthening it.
August 25, 2026
PoradnikiExercise and Depression — What Does the Cochrane Review Show?
"Exercise helps with depression" is one of those recommendations you hear everywhere — from the doctor's office to social media. A Cochrane review covering 39 studies and more than two thousand participants does confirm a moderate effect of exercise on depression. But that same review contains a second, far less frequently cited number: when the analysis was restricted to only the most methodologically rigorous studies, the effect nearly disappeared. This is one of the best available lessons in how to read meta-analyses critically — and why the quality of studies, not just their number, determines the strength of a conclusion.
August 27, 2026
PoradnikiLow Testosterone and Depression: What Does the Research Show?
The link between low testosterone and depression is real, but more modest and less clear-cut than a simple causal story. The largest meta-analysis to date, covering 27 trials and nearly 1,900 men, shows a dose-dependent effect — but it doesn't support the idea that baseline testosterone level predicts who will respond to treatment.
October 3, 2026
Comments (2)
- KW
Kasia W. 2 weeks ago
Very clearly explained, especially the interactions section — I hadn't seen it laid out this well anywhere else.
- MT
Marek T. a month ago
Are you planning to update this with the newest study from this year? I saw an interesting meta-analysis.